In 2012 a study was conducted which established a link between the statin class of medications and the development of Type 2 Diabetes in women, predominantly post-menopausal women.
Subsequently, numerous Lipitor lawsuits have been filed in the USA against pharmaceutical corporation, Pfizer, claiming that Pfizer failed to adequately warn consumers of the risk of developing diabetes associated with the statin.
What is Lipitor?
Lipitor is a cholesterol-lowering drug which reduces blood levels of low density lipoprotein (LDL) cholesterol and belongs to the class of drugs called statins. In 1996, the US Food and Drug Administration (FDA) approved the product and it is one of the world’s top-selling prescription drugs.
What is Lipitor used for?
The medication is frequently prescribed by doctors:-
- to reduce the risk of heart attacks, strokes and chest pain;
- to patients who have already been diagnosed with heart disease.
Other side effects linked to Lipitor:
- Heart attacks;
- Myopathy or Rhabdomyolysis;
- Liver dysfunction;
- Cognitive damage;
- Irreparable damage to nerves, tendons and muscle damage.
What does Pfizer have to say about this?
In February 2012, only after a request by the FDA, Pfizer finally agreed to update and communicate the drug’s association to high blood sugar and increased risk of diabetes on its labelling.
However, the warning does not mention Type 2 Diabetes. Instead the warning labels state: “Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including LIPITOR.”
Several victims are proceeding to file lawsuits against Pfizer in an attempt to obtain compensation for suffering serious side effects from using Lipitor.
Claimants are alleging that Pfizer:
- Marketed Lipitor as safe and effective, although it knew or should have known about the risks of increasing blood glucose levels and developing type 2 diabetes;
- Is liable for “negligent and wrongful conduct in connection with the design, development, manufacture, testing, packaging, promoting, marketing, distribution, labelling, and/or sale of Lipitor”;
- Failed in its duty to monitor Lipitor’s safety;
- Engaged in overly aggressive and misleading marketing, but did not provide patients and their physicians with information that could have prevented injuries.
Talk to a Lipitor specialist advisor today